Be part of the knowledge.™

Oncology and Hematology

838

LikeLikedUnlike

241-255 of 290

Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
- Luis Paz-Ares, MD, PhD
  Peer
- Helena Yu, MD
  Peer
- Matthew Gubens, MD, MS
  Peer
1.00 program credits
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
- Luis Paz-Ares, MD, PhD
  Peer
- Helena Yu, MD
  Peer
- Matthew Gubens, MD, MS
  Peer
1.00 program credits
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CE
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
- Joyce O'Shaughnessy, MD
  Peer
0.25 credits
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CE
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
- David H. Ilson, MD, PhD
  Peer
- Sunnie Kim, MD
  Peer
1.00 credits
The Evolving Role of MET TKIs in NSCLC
CME/CE
The Evolving Role of MET TKIs in NSCLC
- Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
  Peer
- Jyoti Patel, MD
  Peer
0.75 credits
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 credits 10 episodes
advertisement
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
advertisement
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended